Discover Research Opportunities with Xellia's Investigator Initiated Trial (IIT) program

Find out more

Featured news

29 Nov 2023

Xellia starts commercial production and distribution of premix bag products from its Cleveland, USA facility

Read article

What we do

We are a global specialty injectable pharmaceutical company focused on developing solutions and science.

We are a leading provider of essential anti-infectives such as Vancomycin, Colistimethate Sodium, Bacitracin, Polymyxin B and Daptomycin.

With 120 years of experience and backing from Novo Holdings, we are a trusted organization that puts people and patients at the heart of what we do.

Our corporate headquarters are in Copenhagen, Denmark, and we produce products in many locations including the US and Europe.

Additional Daptomycin presentation

After researching common doses of Daptomycin, we focused on solutions to identify additional needed presentations for Daptomycin. Xellia has US FDA approval of both 500 mg and 350 mg Daptomycin.

Read more

Vertically integrated, same NDC

Given the market shortages in the US injectable market, we have focused on solutions to provide multiple sources of injectable products. Xellia is excited to be vertically integrated on API.


Supplying Innovative Solutions

We leverage our expertise in science, research and development to bring innovative solutions to market.

We develop and produce a portfolio of quality, established and innovative injectable products for hospitals.

Our vertical integration strategy from research and development through distribution sets us apart as a unique partner to supply select products. Our team is made up of industry experts who are customer focused and driven to meet your needs.